11/52 | 5003

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE

ATTY. DOCKET NO.
102-525 CIP/DIV (P5258)

Unassigned

STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT CONFIRMATION NO.
Alchas et al. Unassigned

FILING DATE GROUP
Herewith Unassigned

U.S. PATENT DOCUMENTS

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
V		1,934,046	11/07/33	Demarchi			
		2,876,770	03/10/59	White			
		3,400,715	09/10/68	Pederson			
		4,060,073	11/29/77	Collica et al.			
		4,270,537	06/02/81	Romaine			•
		4,373,526	03/15/93	King			
		4,583,978	04/22/86	Porat et al.			·
		4,596,556	06/24/86	Morrow et al.			
		4,769,003	09/06/88	Stamler		\	
		4,790,824	12/13/88	Morrow et al.			
		4,883,573	11/28/89	Thomas			
		4,886,499	12/12/89	Cirelli et al.			
		4,898,588	02/06/90	Roberts			
		4,940,460	07/10/90	Casey, I. et al.			
2/		4,941,880	07/17/90	Burns			
7		4,955,871	09/11/90	Thomas			
EXAMINE	R 🥢	HI HA		DATE CONSIDERED	Augy	× 24	2005

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 102-525 CIP/DIV (P- 5258)		-	SERIAL NO. Unassigned		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT						CONFIRMATION NO.	
	(Use several sheets i	f necessary)	·	FILING (Herewith			GROUI Unassi	
	r 				· · · · · · · · · · · · · · · · · · ·			
\rightarrow	4,978,344	12/18/90	Dombrowski e	t al.			_	
	5,015,235	05/14/91	Crossman					
	5,064,413	11/12/91	McKinnon et a	1.				
	5,071,353	12/10/91	Van der Wal	·····		ļ		
	5,141,496	08/25/92	Dalto et al.					
	5,190,521	03/02/93	Hubbard et al.					
	5,222,949	06/29/93	Kaldany					
	5,295,975	03-1994	Lockwood, Jr.					
	5,312,335	05/17/94	McKinnon et al	l	\			
	5,331,954	07/26/94	Rex et al.	at		<u> </u>		
	5,334,144	08/02/94	Alchas et al.			1		
	5,339,163	08/16/94	Homma et al.			1		
	5,368,578	11/29/94	Covington et a	ı.				
	5,383,851	01/24/95	McKinnon, Jr.	et al.				
	5,417,662	05/23/95	Hjerman et al.					
h	5,431,155	07/11/95	Marelli				_	
(\/_	5,437,647	08/01/95	Firth et al.					
<u>X</u>	5,466,220	11//14/95	Brenneman				7	
EXAMINE	ER MONTH	1	DATE CONSI	DERED	Augu	大 2	4, 2	2005
EVANDER). Initial if aitation a	$\bigvee_{i=1}^{n}$		****				DDD 600 B

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE Rev. 2-32) PATENT AND TRADEMARK OFFICE					CKET NO. CIP/DIV (P-			IAL NO. ssigned
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Alchas et al.		CONFIRMATION NO.	
(Use several sheets if necessary)				FILING D Herewith			GROUP Unassigned	
_/	T T		<u> </u>				I	* .
	5,480,381	01/02/96	Weston		1		\perp	
	5,496,286	03/05/96	Stiehl et al.					
	5,503,627	04/02/96	McKinnon et al	•				
	5,514,107	05/07/96	Haber et al.					····
	5,520,639	05/28/96	Peterson et al.					
	5,527,288	06/18/96	Gross et al.					
	5,569,189	10/29/96	Parsons					
	5,578,014	11/26/96	Erez et al.					
	5,582,598	12/10/96	Chanoch		•			
	5,599,302	02/04/97	Lilley et al.					
	5,649,912	07/22/97	Peterson					
	5,665,071	09/09/97	Wyrick					
	5,702,362	12/30/97	Herold et al.					
	5,704,911	01/06/98	Parsons			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
	5,779,677	07/14/98	Frezza					·
	5,873,856	02/23/99	Hjertman et al.				\prod	· · · · · · · · · · · · · · · · · · ·
	5,879,327	03/09/99	Moreau De Far	ges et al.			$ \bot $	
\	5,891,085	04/96/99	Lilley et al.	· · · · · · · · · · · · · · · · · · ·				\
EXAMIN	er HallA		DATE CONSII	DERED	Auga	st:	24.	2005

	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. 102-525 CIP/DIV (P- 5258)		SERIAL NO. Unassigned	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT							IRMATION NO.	
(Use several sheets if necessary)					FILING DATE GROUP			IP	
	_				Herewith	 		Unass	signed
7	,	5,893,397	04/13/99	Peterson et al.					
		5,921,963	07/13/99	Erez et al.		\			
		5,957,897	09/28/99	Jeffrey					
		5,961,495	10/05/99	Walters et al.					···
		5,993,412	11/30/99	Deily et al.					
	_	6,001,089	12/14/99	Burroughs et a	l.				
		6,004,299	12/21/99	Arai et al.					
		6,036,675	03/14/00	Thorne et al.					
		6,053,893	04/25/00	Bucher	·····				
		6,083,197	07/04/00	Umbaugh					
		6,090,077	07/18/00	Shaw					
		6,090,080	07/18/00	Jost et al.					
		6,090,082	07/18/00	King et al.					
		6,093,170	07/25/00	Hsu et al.			1		
		6,099,504	08-2000	Gross et al.					
<u>_</u>		6,112,743	09/05/00	Denton				\perp	
$\langle \rangle$		6,200,291	03/13/01	DiPietro				$\perp \! \! \! \! \! \! \! \! \perp$	
<u> </u>		6,436,068	08-2002	Bardy					
EXA	IINER X	al HA	TI	DATE CONSIL	ERED	Aug	teu	24	2005
						-			,

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE					OCKET NO. CIP/DIV (P	-	SERIAL NO. Unassigned		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT CONFIRMATION Unassigned				N NO.
(Use several sheets if necessary)					FILING DATE GROUP Herewith Unassigned				
		FOREIG	N PATENT DO	OCUMEN	TS				
EXAMINER	DOCÚMENT	DATE	COUNT	DV	CLASS	SUI		TRANS	LATION
INTRIAL	NUMBER		Coom	NI	\	CLAS	SS	YES	NO
7	2000-37456	02/08/00	Japan						
	DE 41 27 887 C1		Germany						
	EP 0 279 583 B1	10/06/93	EPO						
	EP 0 904 790 A2	20,00,25	EPO					 ,	
	FR 612 401 A1		France	•	1				
	GB 2 206 794 A		United Kingdo	m					
	WO 95/01198		PCT				Ì		
	WO 97/13537	04/17/97	РСТ						
	WO 97/37705	10/16/97	РСТ						
	WO 99/27986		РСТ			\			
	WO 99/34850		РСТ				\prod		
	OTHER DOCUM	ENTS (Incl	uding Author,	Title, Date	e, Pertinen	t Page	s, Et	c.)	
Article: CLINICAL DO's & DON'TS - GIVING INTRADERMAL INJECTIONS by Edwina Mcconnell, RN, PhD									
EXAMINE	EXAMINER HALL DATE CONSIDERED August 24, 2005								

		ARTMENT OF COMMERCE TRADEMARK OFFICE	ATTY. DOCKET NO. 102-525 CIP/DIV (P- 5258)	SERIAL NO. Unassigned				
	STATEM	ATION DISCLOSURE ENT BY APPLICANT	APPLICANT Alchas et al.	CONFIRMATION NO. Unassigned				
	(Use sever	al sheets if necessary)	FILING DATE Herewith	GROUP Unassigned				
	T							
		-						
1.		-						
		Article: DERMAL IMMUNE SYSTEM b	by Brian J. Nickoloff, MD, Ph	D				
(/)								
—								
		Article: INJECTION TECHNIQUE INT	RADERMAL					
$(\ \)$								
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Article: INTRADERMAL CENE IMMLE	NIZATION: THE DOCCIDLE D	OLE OE DNA LIDTAVE IN THE				
\times	Article: INTRADERMAL GENE IMMUNIZATION: THE POSSIBLE ROLE OF DNA UPTAKE IN THE INDUCTION OF CELLULAR IMMUNITY TO VIRUSES by Eyal Raz et al.							
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	•	Article: MONOGRAPHS OF THE PHYS						
\mathcal{L}		PRODUCING PAIN AND ITCH by C.A. Company (1964)	. Keele and D. Armstrong Pu	b: The Williams & Wilkins				
\ / /								
\frac{1}{2}		Article: THE DENDRITIC CELL SYST	EM AND ITS ROLE IN IMMU	NOGENICITY by Raiph				
(')								
		Article: TRIALS OF INTRADERMAL H	EPATITIS B VACCINES IN G	AMBIAN CHILDREN by				
$\overline{}$		Whittle, Lam, Ryder						
(')		Purified Influenza Vaccine: Clinical a Routes of Immunization, by C.A. Phi	and Serologic Responses to lins. B.R. Forsyth. W.A. Chri	Varying Doses and Different stmas D.W. Gumn F.B.				
\ \ \	 	Whorton, I. Rogers, and A. Rudin, fr	om the Department of Medic	cine and Community				
\rightarrow	-	Medicine, University of Vermont Coll	ege of Medicine, Burlington,	Vermont.				
(/)		Polygolant Influence Vessing Com-	unicon of lot Intestion with	Introduced and				
\searrow	Polyvalent Influenza Vaccine: Comparison of Jet Injection with Intradermal and Subcutaneous Syringe Methods of Administration, authored by Mervin L. Clark, Herbert							
-71	 	Reinhardt, M. Clinton Miller, III and	Ray Wilson, Oaklahoma City	, Oklahoma.				
(//		5						
*	<u> </u>	Experimental Comparison of Intrade Vaccine, from the American Journal	rmai and Subcutaneous Vac of Medical Technology, Vol.	cination with Influenza 31, November-December				
		1965, No. 6.						
•	\ /1 k	(1/4)	٨	_				
EXAMINE	ER HAN	DATE CONSI	DERED Avant	~ 2005				
	-/ · · · ·							

		RTMENT OF COMMERCE TRADEMARK OFFICE	ATTY. DOCKET NO. 102-525 CIP/DIV (P- 5258)	SERIAL NO. Unassigned					
	STATEME	TION DISCLOSURE NT BY APPLICANT	APPLICANT Alchas et al.	CONFIRMATION NO. Unassigned					
	(Use several	sheets if necessary)	FILING DATE Herewith	GROUP Unassigned					
		Intradermal Influenza Immunization, Review of Respiratory Disease, Vol. 1	Experience with Hong Kong 03, 1971.	Vaccine, from the American					
9		Efficacy of Adsorbed Trivalent Split Influenza Vaccine Administered by Intradermal Route, by I. Th. Niculescu, Eugenia Zilisteanu, V. Alexandrescu, Mihaela Matepiuc, Ligia Cretescu, N. Ionescu, G. Molnar, R. Racasan and Adina Mogos, received for publication December 4, 1980, from Arch. Roum. Path. Exq. Microbiol., T. 40, No. 1, pp. 67-70, Janvier-Mars, 1981.							
		Efficacy of Intradermally Administered A2 Hong Kong Vaccine, from Jama, from JAMA, July 6, 1970, Vol. 213, No. 1							
		Comparison of Responses to Influenza, A-New Jersey/76-A/Victoria/75 Virus Vaccine Administered Intradermally or Subcutaneously to Adults with Chronic Respiratory Disease, authored by F. Alexander Herbert, R.P. Bryce Larke, and Edythe L. Markstad, from the Journal of Infectious Diseases, Vol. 140, No. 2, August 1979.							
		A Comparison of the Intradermal and Subcutaneous Routes of Influenza Vaccination with A/New Jersey/76 (Swine Flu) and A/Victoria/75: Report of a Study and Review of the Literature, by William Halperin, MD, MPH, William I. Weiss, MD, Ronald Altman, MD, MPH, Michael A. Diamond, MD, Kenneth J. Black, BA, Alfred W. Iaci, BBA, MS, Henry C. Black, DVM and Martin Goldfield, MD, from the ALPHA December 1979, Vol. 69, No. 12.							
		Effect of Dosage and Route of Inoculation Upon Antigenicity of Inactivated Influenza Virus Vaccine (Hong Kong Strain) in Man, from Bull. Org. mond. Santé Bull. Wid Hith Org. 1969, 41, 507-516.							
	_	Comparative Analysis of Six European Influenza Vaccines, from Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15:121-127.							
		Morphological and Biochemical Characterization of Influenza Vaccines Commercially Available in the United Kingdom, by F. Renfrey and A. Watts, from Vaccine 1994, Vol. 12, No. 8.							
		Influenza Immunization Policies and I Diseases, Vol. 141, No. 2, February 1	Practices in Japan, from the 1 980.	lournal of Infectious					
EXAMIN	er Hat	DATE CONSI	DERED Awart	كال 2006					
EYAMINE	D. Initial if air	tation considered whether or not o	itation is in annfarman						

FORM PTO-14 (Rev. 2-32)	49 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 102-525 CIP/DIV (P- 5258) SERIAL NO. Unassigned					
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Alchas et al.	CONFIRMATION NO. Unassigned				
	(Use several sheets if necessary)	FILING DATE GROUP Herewith Unassigned					
	Clinical Immunogenicity and Tolerar and a New Single-Use Cartridge (Im- authored by Isabelle Parent du Chat Georges Soula, Alain Gene, Steven Group, Vaccine 1997, Vol. 15, No. 4	oule®): Comparison with St telet, Jean Lang, Martin Schl M. Standaert, Pierre Saliou a	andard Syringe Injection, umberger, Emmanuel Vidor,				
	Intramuscular Injections?, by Polillic	Abstract: Does a Needleless Injection System Reduce Anxiety in Children Receiving Intramuscular Injections?, by Polillio AM, Kiley J, from the Pediatric Primary Care Clinic, Boston City Hospital, MA, USA. Pediatr. Nurs. 1997, January-February; 23(1): 46-9.					
	Abstract: <i>Intradermal Administratio</i> Imayama S, Hayashi J, Niho Y, from	on <i>of Viral Vaccines,</i> by Naga n Rev. Med. Virol. 1998 April	ıfuchi S., Kashiwagi S, ; 8(2):97-111.				
	Abstract: Letter: Intradermal Influe	enza Vaccination, by Payler [DK, Skirrow MB, Br Med J				
	Intradermal Influenza Vaccination; (British Medical Journal, June	29, 1974.				
\nearrow	Smith Kline Beecham Meeting Agend	da					

EXAMINER

DATE CONSIDERED